CA3026327A1 - Methods and compositions for preventing infection by a vibrio species - Google Patents
Methods and compositions for preventing infection by a vibrio species Download PDFInfo
- Publication number
- CA3026327A1 CA3026327A1 CA3026327A CA3026327A CA3026327A1 CA 3026327 A1 CA3026327 A1 CA 3026327A1 CA 3026327 A CA3026327 A CA 3026327A CA 3026327 A CA3026327 A CA 3026327A CA 3026327 A1 CA3026327 A1 CA 3026327A1
- Authority
- CA
- Canada
- Prior art keywords
- phage
- strains
- icp
- cholerae
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims abstract description 70
- 241000607598 Vibrio Species 0.000 title claims abstract description 55
- 208000015181 infectious disease Diseases 0.000 title claims description 113
- 241000607626 Vibrio cholerae Species 0.000 claims abstract description 174
- 230000002101 lytic effect Effects 0.000 claims abstract description 76
- 241001515965 unidentified phage Species 0.000 claims abstract description 76
- 230000001580 bacterial effect Effects 0.000 claims abstract description 74
- 206010008631 Cholera Diseases 0.000 claims abstract description 66
- 241000894007 species Species 0.000 claims abstract description 24
- 230000003115 biocidal effect Effects 0.000 claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims description 103
- 101001044255 Entamoeba histolytica Amoebiasin-2 Proteins 0.000 claims description 51
- 101001042083 Entamoeba histolytica Amoebiasin-1 Proteins 0.000 claims description 50
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 40
- 238000010171 animal model Methods 0.000 claims description 20
- 208000035143 Bacterial infection Diseases 0.000 claims description 16
- 239000002158 endotoxin Substances 0.000 claims description 16
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 16
- 239000003242 anti bacterial agent Substances 0.000 claims description 15
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 210000002845 virion Anatomy 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 11
- 230000000069 prophylactic effect Effects 0.000 claims description 11
- 206010047400 Vibrio infections Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940118696 vibrio cholerae Drugs 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 230000007613 environmental effect Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 241001453243 Campylobacter sputorum subsp. bubulus Species 0.000 claims description 4
- 241000332146 Vibrio aerogenes Species 0.000 claims description 4
- 241001676766 Vibrio aestivus Species 0.000 claims description 4
- 241001135143 Vibrio aestuarianus Species 0.000 claims description 4
- 241001231453 Vibrio albensis Species 0.000 claims description 4
- 241000607594 Vibrio alginolyticus Species 0.000 claims description 4
- 241000544286 Vibrio anguillarum Species 0.000 claims description 4
- 241001500064 Vibrio areninigrae Species 0.000 claims description 4
- 241000452627 Vibrio artabrorum Species 0.000 claims description 4
- 241000607323 Vibrio campbellii Species 0.000 claims description 4
- 241000944835 Vibrio casei Species 0.000 claims description 4
- 241000607296 Vibrio cincinnatiensis Species 0.000 claims description 4
- 241001025870 Vibrio crassostreae Species 0.000 claims description 4
- 241000607306 Vibrio diazotrophicus Species 0.000 claims description 4
- 241001349548 Vibrio ezurae Species 0.000 claims description 4
- 241001180047 Vibrio gigantis Species 0.000 claims description 4
- 241000965623 Vibrio lentus Species 0.000 claims description 4
- 241001135144 Vibrio metschnikovii Species 0.000 claims description 4
- 241000501793 Vibrio mytili Species 0.000 claims description 4
- 241000607365 Vibrio natriegens Species 0.000 claims description 4
- 241000681718 Vibrio neptunius Species 0.000 claims description 4
- 241000607359 Vibrio nereis Species 0.000 claims description 4
- 241000690895 Vibrio pacinii Species 0.000 claims description 4
- 241000896074 Vibrio pectenicida Species 0.000 claims description 4
- 241001517161 Vibrio pomeroyi Species 0.000 claims description 4
- 241001290502 Vibrio rumoiensis Species 0.000 claims description 4
- 241000193098 Vibrio scophthalmi Species 0.000 claims description 4
- 241001148079 Vibrio splendidus Species 0.000 claims description 4
- 241000510690 Vibrio tapetis Species 0.000 claims description 4
- 241001552442 Vibrio tasmaniensis Species 0.000 claims description 4
- 241000607265 Vibrio vulnificus Species 0.000 claims description 4
- 230000000670 limiting effect Effects 0.000 claims description 4
- 241000607337 Aliivibrio logei Species 0.000 claims description 3
- 241000305093 Enterovibrio calviensis Species 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241001656470 Vibrio agarivorans Species 0.000 claims description 3
- 241000762753 Vibrio alfacsensis Species 0.000 claims description 3
- 241000549284 Vibrio atypicus Species 0.000 claims description 3
- 241000674191 Vibrio azureus Species 0.000 claims description 3
- 241001407018 Vibrio coralliilyticus Species 0.000 claims description 3
- 241000501799 Vibrio diabolicus Species 0.000 claims description 3
- 241000607291 Vibrio fluvialis Species 0.000 claims description 3
- 241001552433 Vibrio fortis Species 0.000 claims description 3
- 241001148070 Vibrio furnissii Species 0.000 claims description 3
- 241001407022 Vibrio gallicus Species 0.000 claims description 3
- 241000607339 Vibrio gazogenes Species 0.000 claims description 3
- 241001234514 Vibrio halioticoli Species 0.000 claims description 3
- 241000607618 Vibrio harveyi Species 0.000 claims description 3
- 241000210080 Vibrio hippocampi Species 0.000 claims description 3
- 241001268204 Vibrio ichthyoenteri Species 0.000 claims description 3
- 241000944752 Vibrio indicus Species 0.000 claims description 3
- 241000690894 Vibrio kanaloae Species 0.000 claims description 3
- 241000607334 Vibrio mediterranei Species 0.000 claims description 3
- 241001148073 Vibrio navarrensis Species 0.000 claims description 3
- 241001135145 Vibrio nigripulchritudo Species 0.000 claims description 3
- 241001135139 Vibrio ordalii Species 0.000 claims description 3
- 241001135140 Vibrio orientalis Species 0.000 claims description 3
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims description 3
- 241001490532 Vibrio penaeicida Species 0.000 claims description 3
- 241000607269 Vibrio proteolyticus Species 0.000 claims description 3
- 241001407024 Vibrio rotiferianus Species 0.000 claims description 3
- 241001086881 Vibrio ruber Species 0.000 claims description 3
- 241001517090 Vibrio superstes Species 0.000 claims description 3
- 241001148039 Vibrio tubiashii Species 0.000 claims description 3
- 241000681724 Vibrio xuii Species 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000002269 spontaneous effect Effects 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241000122170 Aliivibrio salmonicida Species 0.000 claims description 2
- 241000726096 Aratinga Species 0.000 claims description 2
- 101710116435 Outer membrane protein Proteins 0.000 claims description 2
- 241001520299 Phascolarctos cinereus Species 0.000 claims description 2
- 241000287531 Psittacidae Species 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 241000607253 Vibrio mimicus Species 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000000884 anti-protozoa Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 238000009155 rehydration therapy Methods 0.000 claims description 2
- 241001672646 Vibrio atlanticus Species 0.000 claims 2
- 241000690888 Vibrio chagasii Species 0.000 claims 2
- 241000694781 Vibrio hepatarius Species 0.000 claims 2
- 241000276415 Vibrio hispanicus Species 0.000 claims 2
- 241000681719 Vibrio brasiliensis Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 48
- 230000035772 mutation Effects 0.000 abstract description 30
- 201000010099 disease Diseases 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 22
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 55
- 210000000813 small intestine Anatomy 0.000 description 37
- 238000011321 prophylaxis Methods 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 230000002829 reductive effect Effects 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 239000012530 fluid Substances 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 18
- 239000013543 active substance Substances 0.000 description 17
- 239000000427 antigen Substances 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 230000005540 biological transmission Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 210000000936 intestine Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241000282412 Homo Species 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 244000052616 bacterial pathogen Species 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000002147 killing effect Effects 0.000 description 9
- 101100214867 Autographa californica nuclear polyhedrosis virus AC53 gene Proteins 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920002101 Chitin Polymers 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 241000736262 Microbiota Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000001018 virulence Effects 0.000 description 7
- 108700023313 Bacteriophage Receptors Proteins 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- -1 calreticul in Chemical class 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 238000007747 plating Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000006137 Luria-Bertani broth Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000011555 rabbit model Methods 0.000 description 5
- 201000009881 secretory diarrhea Diseases 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010022678 Intestinal infections Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000001320 lysogenic effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000001066 phage therapy Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 238000012268 genome sequencing Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241001600138 Aliivibrio wodanis Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 240000004381 Verbena brasiliensis Species 0.000 description 2
- 241000602423 Vibrio cholerae O1 Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000011201 multiple comparisons test Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 101150055431 ompU gene Proteins 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 101150021331 toxR gene Proteins 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101100284517 Aneurinibacillus thermoaerophilus hddC gene Proteins 0.000 description 1
- QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000348 Angiotensin-3 Human genes 0.000 description 1
- 101800000738 Angiotensin-3 Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241001243567 Atlanticus Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282805 Ceratotherium simum Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 101710105759 Major outer membrane porin Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000702072 Podoviridae Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000219284 Vibrio cyclitrophicus Species 0.000 description 1
- 241000369309 Vibrio litoralis Species 0.000 description 1
- 241000092104 Vibrio ponticus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000005567 fecaloral disease transmission Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 101150039741 hldD gene Proteins 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000037971 neglected tropical disease Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- UEHGPSGGFKLPTD-KVTDHHQDSA-N perosamine Chemical compound C[C@@H](O)[C@@H](N)[C@H](O)[C@H](O)C=O UEHGPSGGFKLPTD-KVTDHHQDSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- MFZOSKPPVCIFMT-UHFFFAOYSA-N pinazepam Chemical compound C12=CC(Cl)=CC=C2N(CC#C)C(=O)CN=C1C1=CC=CC=C1 MFZOSKPPVCIFMT-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000000899 pressurised-fluid extraction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013376 serial cultivation Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 101150101459 tx gene Proteins 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316704P | 2016-04-01 | 2016-04-01 | |
| US62/316,704 | 2016-04-01 | ||
| PCT/US2017/025305 WO2017173229A1 (en) | 2016-04-01 | 2017-03-31 | Methods and compositions for preventing infection by a vibrio species |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3026327A1 true CA3026327A1 (en) | 2017-10-05 |
Family
ID=59966476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3026327A Abandoned CA3026327A1 (en) | 2016-04-01 | 2017-03-31 | Methods and compositions for preventing infection by a vibrio species |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10953053B2 (enExample) |
| EP (1) | EP3436611A4 (enExample) |
| JP (1) | JP2019510052A (enExample) |
| KR (4) | KR20240005101A (enExample) |
| CN (1) | CN109310722A (enExample) |
| CA (1) | CA3026327A1 (enExample) |
| WO (1) | WO2017173229A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109517804A (zh) * | 2018-11-19 | 2019-03-26 | 扬州大学 | 一种具有跨种裂解特性的拟态弧菌噬菌体oy-1、制备方法及其应用 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
| CN107904211B (zh) * | 2017-10-13 | 2024-03-19 | 深圳先进技术研究院 | 副溶血弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904214A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107805629B (zh) * | 2017-10-13 | 2023-03-21 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904212A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107805630B (zh) * | 2017-10-13 | 2024-03-19 | 深圳先进技术研究院 | 副溶血弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904213A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN108048412A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-4及包含该噬菌体的杀菌组合物及其应用 |
| CN107988172A (zh) * | 2017-11-20 | 2018-05-04 | 深圳先进技术研究院 | 裂性弧菌噬菌体VpaJT-1及包含该噬菌体的杀菌组合物及其应用 |
| CN107988171A (zh) * | 2017-11-20 | 2018-05-04 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValSw4-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108048411A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-2及包含该噬菌体的杀菌组合物及其应用 |
| CN108048410B (zh) * | 2017-11-20 | 2023-06-27 | 深圳先进技术研究院 | 裂性弧菌噬菌体VspSw-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108070570A (zh) * | 2017-11-20 | 2018-05-25 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValDsh-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108048409A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-3及包含该噬菌体的杀菌组合物及其应用 |
| CN112236517A (zh) * | 2018-05-22 | 2021-01-15 | 学校法人自治医科大学 | 抗菌噬菌体、治疗用组合物、杀菌剂、食品、细菌鉴别试剂盒、治疗用组合物制造方法、细菌去除方法、细菌鉴别方法及动物治疗方法 |
| CN110352880B (zh) * | 2019-08-13 | 2021-04-20 | 宁波大学 | 一种紫菜黄斑病的治疗方法 |
| CN112391358B (zh) * | 2019-08-14 | 2023-12-01 | 宁波大学 | 地中海弧菌烈性噬菌体vB_VmeM-Yong及其应用 |
| CN111826309A (zh) * | 2020-06-30 | 2020-10-27 | 武汉合缘绿色生物股份有限公司 | 一种液体生物营养菌剂及其制备方法 |
| CN112029733B (zh) * | 2020-09-24 | 2021-11-26 | 瑞科盟(青岛)生物工程有限公司 | 一株高裂解性溶藻弧菌噬菌体rdp-vp-19001及其应用 |
| CN112011520B (zh) * | 2020-10-30 | 2021-01-19 | 中国科学院南海海洋研究所 | 一种调控珊瑚菌群的温和噬菌体VneM1及其应用 |
| CN112553171B (zh) * | 2020-12-27 | 2022-06-21 | 威海长青海洋科技股份有限公司 | 一种弧菌噬菌体制剂及其应用 |
| CN112646786A (zh) * | 2021-01-21 | 2021-04-13 | 海南海壹水产种苗有限公司 | 一株坎式弧菌噬菌体快速初步分离方法 |
| CN113201505B (zh) * | 2021-04-02 | 2023-12-29 | 青岛诺安百特生物技术有限公司 | 一株具备跨种裂解能力的溶藻弧菌噬菌体、其噬菌体组合物及其应用 |
| KR102774411B1 (ko) * | 2021-10-27 | 2025-02-27 | 전북대학교산학협력단 | 재증식 풀 컬쳐 기반 박테리오파지 스크리닝 방법 |
| CN116103183A (zh) * | 2022-03-30 | 2023-05-12 | 山东科技大学 | 一株脱除高盐硬水中钙离子的巨大弧菌及其应用 |
| CN114774371B (zh) * | 2022-06-21 | 2022-09-13 | 中国海洋大学 | 一种弧菌噬菌体及其应用 |
| CN115820569B (zh) * | 2022-08-09 | 2025-01-14 | 青岛诺安百特生物技术有限公司 | 一株奥氏弧菌噬菌体、其噬菌体组合物及其应用 |
| KR20240058217A (ko) | 2022-10-25 | 2024-05-03 | 주식회사 엘지에너지솔루션 | 고분자 고체 전해질 및 이의 제조방법 |
| CN120058874B (zh) * | 2025-04-29 | 2025-09-09 | 中国疾病预防控制中心传染病预防控制所 | 噬菌体蛋白Gp37及其在制备抑制霍乱弧菌定植和毒素分泌的制剂中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2186962A1 (en) | 1994-04-05 | 1995-10-12 | Richard M. Carlton | Antibacterial therapy with genotypically modified bacteriophage |
| AU4313101A (en) | 2000-01-11 | 2001-07-24 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
| US8956628B2 (en) | 2007-12-13 | 2015-02-17 | Zoetis Products Llc | Bacteriophage preparations and method of use thereof |
| CL2012002902A1 (es) * | 2012-10-17 | 2013-05-03 | Univ Chile | Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas. |
| US9839657B2 (en) * | 2012-10-30 | 2017-12-12 | Deerland Enzymes, Inc. | Prebiotic compositions comprising one or more types of bacteriophage |
| WO2015034872A2 (en) * | 2013-09-05 | 2015-03-12 | Massachusetts Institute Of Technology | Tuning microbial populations with programmable nucleases |
-
2017
- 2017-03-31 JP JP2018551147A patent/JP2019510052A/ja active Pending
- 2017-03-31 CN CN201780033655.0A patent/CN109310722A/zh active Pending
- 2017-03-31 EP EP17776749.8A patent/EP3436611A4/en not_active Withdrawn
- 2017-03-31 WO PCT/US2017/025305 patent/WO2017173229A1/en not_active Ceased
- 2017-03-31 CA CA3026327A patent/CA3026327A1/en not_active Abandoned
- 2017-03-31 KR KR1020237043358A patent/KR20240005101A/ko not_active Ceased
- 2017-03-31 KR KR1020187031275A patent/KR20190005846A/ko not_active Ceased
- 2017-03-31 KR KR1020237030274A patent/KR102755264B1/ko active Active
- 2017-03-31 KR KR1020227033895A patent/KR20220138015A/ko not_active Ceased
-
2018
- 2018-09-28 US US16/145,836 patent/US10953053B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109517804A (zh) * | 2018-11-19 | 2019-03-26 | 扬州大学 | 一种具有跨种裂解特性的拟态弧菌噬菌体oy-1、制备方法及其应用 |
| CN109517804B (zh) * | 2018-11-19 | 2022-06-14 | 扬州大学 | 一种具有跨种裂解特性的拟态弧菌噬菌体oy-1、制备方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019510052A (ja) | 2019-04-11 |
| KR20190005846A (ko) | 2019-01-16 |
| KR102755264B1 (ko) | 2025-01-21 |
| EP3436611A1 (en) | 2019-02-06 |
| US20190099459A1 (en) | 2019-04-04 |
| US10953053B2 (en) | 2021-03-23 |
| KR20240005101A (ko) | 2024-01-11 |
| KR20220138015A (ko) | 2022-10-12 |
| KR20230132886A (ko) | 2023-09-18 |
| WO2017173229A1 (en) | 2017-10-05 |
| CN109310722A (zh) | 2019-02-05 |
| EP3436611A4 (en) | 2019-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10953053B2 (en) | Methods and compositions for preventing infection by a Vibrio species | |
| Yuan et al. | Efficacy of a phage cocktail in controlling phage resistance development in multidrug resistant Acinetobacter baumannii | |
| JP2019510052A5 (enExample) | ||
| KR101070938B1 (ko) | 신규한 박테리오파지 및 이를 포함하는 항균 조성물 | |
| Islam et al. | Application of a novel phage ZPAH7 for controlling multidrug-resistant Aeromonas hydrophila on lettuce and reducing biofilms | |
| TWI459951B (zh) | 新穎噬菌體及含該噬菌體之抗菌組成物 | |
| JP5666016B2 (ja) | 新規バクテリオファージ及びそれを含む抗菌組成物 | |
| US8846368B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
| Nicolas et al. | In ovo administration of a phage cocktail partially prevents colibacillosis in chicks | |
| Royam et al. | Isolation, characterization, and efficacy of bacteriophages isolated against Citrobacter spp. an in vivo approach in a zebrafish model (Danio rerio) | |
| US10898531B2 (en) | Vibrio parahaemolyticus bacteriophage Vib-PAP-5 and use thereof for suppressing proliferation of Vibrio parahaemolyticus bacteria | |
| CN113891721A (zh) | 用于调节炎症性肠病的噬菌体 | |
| US11826391B2 (en) | Antibacterial formulation comprising a mixture of bacteriophages; use and method for preventing or treating diseases caused by salmonella spp. in farm animals by oral administration of the formulation | |
| US8771936B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
| Islam et al. | Determination of optimum survivability factors of highly pathogenic Vibrio cholerae 01 serogroup specific bacteriophage JSF4ϕ | |
| Acton | A Functional Genomics Approach for Improved Bacteriophage Cocktail Design | |
| Jumaniyazova et al. | Isolation and characterization of a novel Salmonella polyvalent bacteriophage ‘MediPhag’in Uzbekistan | |
| Fong | Comparative analysis of Salmonella-infecting bacteriophages and characterization of bacteriophage-host interactions | |
| US11351210B2 (en) | Lactococcus garvieae bacteriophage Lac-GAP-3 and use thereof in inhibiting proliferation of Lactococcus garvieae bacteria | |
| Zaib et al. | In-vitro evaluation and efficacy of bacteriophage isolated from commercial poultry farms against Salmonella typhimurium | |
| TAMALE et al. | Bacteriophage Action against Tilapia Fish Aeromonasis in Aquarium Tanks in Uganda | |
| Soltys | Linking Epidemiologically Distinct Genotypes to Phenotypes of Salmonella Kentucky | |
| Dubey | Isolation and characterization of lytic phages to reduce the risk of vibrio parahaemolyticus infection in aquaculture environment | |
| 김현중 | Identification of causative agents with high mortality in marine bivalve and application of bacteriophage to prevent Vibrio coralliilyiticus infection | |
| Carrias | Evaluation of biological agents for controlling enteric septicemia of catfish |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230628 |